Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03825224 · ClinicalTrials.gov registry record

Evaluation of MyoStrain™ in Clinical Practice

A clinical trial of Coronary Artery Disease and Amyloidosis, sponsored by University of Kansas Medical Center.

Completed
Registry status
19
Enrollment target
1
Study location

NCT03825224: Completed study of Coronary Artery Disease and Amyloidosis, sponsored by University of Kansas Medical Center.

NCT03825224 is a study of Coronary Artery Disease and Amyloidosis that has completed, run by University of Kansas Medical Center. The registered enrollment target is 19 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03825224, a study of Coronary Artery Disease and Amyloidosis, has completed, sponsored by University of Kansas Medical Center.

COMPLETED
Registry status
19 participants
Enrollment target
1
Study location

Study Summary

Evaluate MyoStrain cardiac MRI pulse sequence in Clinical practice

Primary Outcome

Survey the CMR interpreter to see how Myostrain impacted their interpretation and survey the referring clinician after receiving the CMR report. Survey Questions using 5-point Likert and binary reporting scale. The lower numbers represent positive feedback. Example listed below: CARDIAC MRI INTERPRETATION QUESTIONS FOR READER (CARDIOLOGIST OR RADIOLOGIST) How easy was it to interpret the additional Myostrain sequence information? 1 2 3 4 5 (1=Very Helpful 2=Helpful 3=Indifferent 4=Unhelpful

Conditions Studied

Coronary Artery Disease Amyloidosis Sarcoidosis Lupus Myocarditis Cardiac Failure Drug Toxicity

Interventions

  • PROCEDURE Diagnostic Test: Myostrain

Study Locations (1)

Kansas

  • The University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2019-04-15
Est. Completion 2019-11-15
University of Kansas Medical Center

408 total trials

What the finished NCT03825224 record still lists

NCT03825224 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (99% lower).

The record links to 7 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Diagnostic Test: Myostrain is the first listed.

NCT03825224 reports a single indexed study location in Kansas.

Frequently Asked Questions

What is clinical trial NCT03825224 about?

NCT03825224 is a clinical study titled "Evaluation of MyoStrain™ in Clinical Practice". Evaluate MyoStrain cardiac MRI pulse sequence in Clinical practice

What is the current status of trial NCT03825224?

This trial is currently completed. The enrollment target is 19 participants. The study started on 2019-04-15. Estimated completion is 2019-11-15.

What conditions does trial NCT03825224 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Amyloidosis, Sarcoidosis, Lupus, Myocarditis.

What interventions are being tested in trial NCT03825224?

The interventions under investigation include: Diagnostic Test: Myostrain (PROCEDURE).

Who is sponsoring clinical trial NCT03825224?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03825224 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03825224's enrollment target sits among peer trials

19 210th of 219 higher than 9 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03825224, the US trial registry maintained by the National Library of Medicine. NCT03825224 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.